drugset / Trial / NCT02874248

E4/DRSP Single and Multiple Dose PK and Early QT Study

NCT02874248

Phase 1 Completed 55 enrolled Estetra
RandomizedParallel-groupDouble-blindOther

Summary

This study is conducted to evaluate the effect of single and multiple therapeutic and supratherapeutic oral doses of E4/DRSP combinations on PK parameters, safety, tolerability and on cardiac repolarization, as detected by QT interval corrected with Fridericia's formula (QTcF).

Timeline

Start
2016-05
Primary completion
2016-11-21
Completion
2016-11-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator ESTETROL ANHYDROUS Other / unclassified 15 mg Oral
Comparator ESTETROL ANHYDROUS Other / unclassified 30 mg Oral
Comparator ESTETROL ANHYDROUS Other / unclassified 60 mg Oral
Comparator ESTETROL ANHYDROUS Other / unclassified 75 mg Oral
Comparator drospirenone Unknown 3 mg Oral
Comparator drospirenone Unknown 6 mg Oral
Comparator drospirenone Unknown 12 mg Oral
Comparator drospirenone Unknown 15 mg Oral

Indications

No indication recorded.